W19--Epidemiology & Clinical Impact of Infection in CF

Chair(s)

• 

  Drake Bouzek, MD

  University of Iowa
• JH

  Jordana Hoppe

  University of Colorado

This session will be of interest to clinicians, basic and clinical researchers, and the wider CF audience. People with CF experience recurrent and often chronic respiratory and GI infections, even in the presence of highly effective CFTR modulator therapy. Modulator therapy has improved respiratory and nutritional outcomes in people with CF for those eligible for treatment. Identifying the prevalence of typical CF pathogens in the modulator era, evaluating novel approaches for monitoring chronic infection as the availability of clinical samples changes, and understanding how infection impacts clinical outcomes of people with CF are essential to guiding the management of infections going forward. In this session we will discuss 1) epidemiological shifts in traditional CF pathogens in people with CF given the prevalence of modulator therapy, 2) approaches for monitoring clinically relevant infection, and 3) clinical outcomes of infection in people with CF in the modulator era.

Presentations:

• 10:15 AM - 12:15 PM PDT

  W19.1- Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on healthcare resource utilization (HCRU) over three years in LONGITUDE – a UK CF Registry observational study
  

  Speaker: Carl Baxter, n/a – Vertex Pharmaceuticals
• 10:15 AM - 12:15 PM PDT

  W19.2- Risk factors for pulmonary exacerbation in people with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor who stop chronic daily therapies
  

  Speaker: Clement Ren, MD – Children's Hospital of Philadelphia
• 10:15 AM - 12:15 PM PDT

  W19.3- Epidemiology of Pseudomonas aeruginosa infection before and after the 2013 Infection Prevention and Control Guidelines
  

  Speaker: Lindsay J. Caverly, MD – University of Michigan Medical School
• 10:15 AM - 12:15 PM PDT

  W19.4- The CF Home Sputum-Induction Trial (CF-HomeSpIT) : Primary outcome data for early morning sputum-induction at home compared to same-day sputum-induction in clinic.
  

  Speaker: Julian T. Forton – The Children's Hospital for Wales, Cardiff, UK
• 10:15 AM - 12:15 PM PDT

  W19.5- Evaluating the clinical utility of oropharyngeal swabs from children with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor using shotgun metagenomics
  

  Speaker: Drake C. Bouzek, MD – University of Iowa